The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology
• Pharmacology

Background:

• Exercise-induced bronchoconstriction (EIB) is a common condition in children with asthma.
• Current treatments for EIB often involve short-acting bronchodilators, but alternative or adjunctive therapies are being explored.

Purpose of the Study:

• To evaluate the single-dose protective effects of montelukast (5 mg) and loratadine (10 mg) combination therapy against EIB in asthmatic children.
• To compare the efficacy of the combination treatment against placebo, montelukast alone, and loratadine alone.

Main Methods:

• A double-blind, randomized, single-dose, crossover study involving 19 children with asthma.
• Participants underwent treadmill exercise tests 2 and 12 hours after receiving single doses of placebo, montelukast, loratadine, or the combination.
• The primary outcome measure was the maximum fall in forced expiratory volume in one second (FEV1).

Main Results:

• No significant difference in FEV1 fall was observed 2 hours post-treatment compared to placebo.
• Significant differences in FEV1 fall were noted 12 hours after administration.
• Montelukast alone and the montelukast-loratadine combination were significantly more effective than loratadine alone at 12 hours.
• The combination treatment did not show significant additive bronchoprotective effects compared to montelukast alone.

Conclusions:

• Maximal protective effect of single-dose montelukast against EIB in children with asthma is achieved 12 hours post-administration.
• Combination therapy with montelukast and loratadine does not provide significant additive bronchoprotective benefits over montelukast alone for EIB.
• Single-dose montelukast demonstrates efficacy in managing EIB in pediatric asthma patients.